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A genome-wide cross-phenotype meta-analysis of
the association of blood pressure with migraine
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Consortium*, The 23andMe Research Team*, Tobias Kurth3,4 & Daniel I. Chasman1,2✉
Blood pressure (BP) was inconsistently associated with migraine and the mechanisms of BP-
lowering medications in migraine prophylaxis are unknown. Leveraging large-scale summary
statistics for migraine (Ncases/Ncontrols= 59,674/316,078) and BP (N= 757,601), we find
positive genetic correlations of migraine with diastolic BP (DBP, rg= 0.11, P= 3.56 × 10−06)
and systolic BP (SBP, rg= 0.06, P= 0.01), but not pulse pressure (PP, rg=−0.01, P= 0.75).
Cross-trait meta-analysis reveals 14 shared loci (P≤ 5 × 10−08), nine of which replicate
(P < 0.05) in the UK Biobank. Five shared loci (ITGB5, SMG6, ADRA2B, ANKDD1B, and
KIAA0040) are reinforced in gene-level analysis and highlight potential mechanisms involving
vascular development, endothelial function and calcium homeostasis. Mendelian randomi-
zation reveals stronger instrumental estimates of DBP (OR [95% CI]= 1.20 [1.15–1.25]/10
mmHg; P= 5.57 × 10−25) on migraine than SBP (1.05 [1.03–1.07]/10mmHg; P= 2.60 ×
10−07) and a corresponding opposite effect for PP (0.92 [0.88–0.95]/10mmHg; P= 3.65 ×
10−07). These findings support a critical role of DBP in migraine susceptibility and shared
biology underlying BP and migraine.
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M igraine is a chronic intermittent neurological disorderaffecting up to 14.7% people worldwide and ranksas the second leading cause of disability, responsible for
5.6% of all years lived with disability1. The link between migraine
and the vascular system has been substantiated by an array of
physiologic and epidemiologic evidence, including migraine
comorbidities with other vascular conditions including stroke,
coronary artery disease (CAD)2. Recently, additional evidence for
vascular involvement in migraine has emerged from genome-
wide association studies (GWAS)3. Approximately, 40% (13 of
38) of the genome-wide significant GWAS loci for migraine map
near genes with known or suspected vascular functions, including
vascular development, endothelial structure, and smooth muscle
function. Loci mapping to the END1/PHACTR1, LRP1, and FHL5
genes in particular are shared by migraine and CAD or cervical
artery dissection4,5.
Blood pressure (BP) has been associated not only with vascular
disease but also with migraine6. In contrast to highly consistent
associations of increased BP with increased susceptibility to vas-
cular disease, associations of BP with migraine are not con-
sistent7. For example, some studies have found associations
between elevated systolic BP (SBP) or diastolic BP (DBP) and
lower prevalence of migraine8, whereas some have found inverse
associations only for SBP9,10. One study suggested that migraine
was associated with higher DBP but lower SBP11. Still other
reports focused on pulse pressure (PP), defined as the difference
between SBP and DBP, consistently showed an inverse relation-
ship between PP and migraine9,11. The relationship is further
complicated by longitudinal studies suggesting that migraine may
increase the risk of incident hypertension12,13, whereas BP has
been found to be inversely related to onset of headache and
migraine14. Regardless, BP-lowering medications notably provide
prophylactic benefit for many migraineurs, and the choice of
antihypertensive appears to be related to comorbidities, cost,
availability, or side effect profile rather than the specific
mechanism of BP-lowering15,16.
Recently developed but widely accepted genetic methods
leveraging only GWAS summary statistics may be used to esti-
mate global17 and local genetic correlation18 between BP mea-
sures (i.e. SBP, DBP, or PP) and migraine. Additional genetic
methods using GWAS summary statistics, including cross-trait
meta-analysis19 and transcriptome-wide association study
(TWAS)20, may be used to identify specific shared genetic com-
ponents and pathophysiology between BP and migraine. Finally,
instrumental genetic analysis, i.e. Mendelian randomization
(MR), may suggest causality and directionality of effects of BP on
migraine, or the reverse, i.e. migraine influences on BP21.
Therefore, in the current study, we leverage large-scale genetic
summary-level data and the preceding genetic methods to gain
insight into mechanistic links between BP and migraine.
Our analysis identifies positive overall genetic correlations of
migraine with DBP and SBP, but not PP, and evidence of local
genetic overlap with BP at certain previously identified migraine
loci after accounting for multiple testing. Cross-trait meta-ana-
lysis reveals shared loci between BP and migraine, some of which
are also reinforced in gene-level analysis highlighting potential
shared biological mechanisms. In addition, MR shows stronger
instrumental estimates of DBP on migraine than SBP. Our results
suggest a critical role of DBP in migraine susceptibility and
shared biological mechanisms between BP and migraine.
Results
Shared heritability between migraine and blood pressure. There
was a positive overall genetic correlation of migraine with DBP (rg
= 0.11, Wald test P= 3.56 × 10−06) and SBP (rg= 0.06, Wald test
P= 0.01), but not PP (rg=−0.01, Wald test P= 0.75) using
linkage disequilibrium (LD) score regression (LDSC) (Table 1).
When extended to the migraine subtypes: migraine with aura
(MA) and migraine without aura (MO), DBP was consistently
correlated with both MA (rg= 0.17, Wald test P= 1.50 × 10−03)
and MO (rg= 0.14, Wald test P= 1.20 × 10−03), whereas SBP was
only marginally correlated with MA (rg= 0.10, Wald test P=
0.04). Findings for genetic covariance analyzer (GNOVA), which
included SNPs with lower minor allele frequency (MAF) than
LDSC, were similar with rg of 0.12 (Wald test P= 3.45 × 10−07),
0.07 (Wald test P= 4.64 × 10−03), and 0.00 (Wald test P= 0.94)
for DBP, SBP, and PP, respectively (Table 1). Partitioned genetic
correlation did not reveal strong contrasts but suggested that
shared effects were concentrated in some chromosomes with the
Table 1 Genetic correlation between migraine and blood pressure.
Method Trait 1 Trait 2 rg P* gcov gcov_se
LDSC Any migraine DBP 0.11 3.56 × 10−06 0.018 0.009
SBP 0.06 0.01 0.004 0.009
PP −0.01 0.75 −0.009 0.008
Migraine with aura DBP 0.17 1.50 × 10−03 −0.006 0.008
SBP 0.10 0.04 −0.014 0.008
PP 0.00 0.92 −0.015 0.007
Migraine without aura DBP 0.14 1.20 × 10−03 0.014 0.008
SBP 0.03 0.43 0.010 0.008
PP −0.08 0.06 0.002 0.007
GNOVA Any migraine DBP 0.12 3.45 × 10−07 0.009 0.002
SBP 0.07 4.64 × 10−03 0.005 0.002
PP 0.00 0.94 0.000 0.002
Migraine with aura DBP 0.15 1.90 × 10−05 0.008 0.002
SBP 0.10 2.57 × 10−03 0.006 0.002
PP 0.03 0.33 0.002 0.002
Migraine without aura DBP 0.13 1.86 × 10−04 0.008 0.002
SBP −0.02 0.66 −0.001 0.002
PP −0.12 2.12 × 10−04 −0.006 0.002
rg Genetic correlation, gcov genetic covariance, gcov_se standard error of genetic covariance, LDSC LD score regression, GNOVA genetic covariance analyzer, DBP diastolic blood pressure, SBP systolic
blood pressure, PP pulse pressure.
*P-value was calculated for the genetic correlation in LDSC and for the genetic covariance in GNOVA, P-values are based on two-sided Wald test.
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strongest positive genetic correlation observed at chr22 (rg= 0.47,
Wald test P= 1.37 × 10−04) between migraine and DBP, and the
strongest negative genetic correlation observed at chr19 (rg=
−0.32, Wald test P= 1.28 × 10−03) between migraine and PP
(Supplementary Figs. 10–21).
The local genomic regions around individual migraine loci from
GWAS showed signals of genetic overlap with BP (Fig. 1).
Accounting for multiple testing, there was genome-wide significant
local genetic correlation between migraine and BP at three regions
(chr6: 94441175..97093511 harboring previous migraine locus
FHL5; chr7: 39862670..42001811 harboring previous migraine
locus C7orf10; and chr10: 95396368..96221243 harboring previous
migraine locus PLCE1) using heritability estimation from summary
statistics (ρ-HESS) (Fig. 1 and Supplementary Table 1, P < 0.05/
1703). The genetic correlation between migraine and SBP was
negative in the chromosome 7 region despite being positive across
the whole genome (Fig. 1). For PP, although the overall genome-
wide genetic correlation with migraine was null, there were
significant local genetic correlations at chromosome 6 (Wald test
P= 3.20 × 10−06) and 7 (Wald test P= 3.98 × 10−08), which were
also significantly correlated for the other BP measures. Results were
consistent for these regions with the alternative pairwise traits
analysis of GWAS (GWAS-PW) approach (i.e. PPA_3 > 0.9, Fig. 1
and Supplementary Table 2).
Taken together, although the overall genetic correlations
between BP traits and migraine were relatively modest compared
to more closely related phenotypes, e.g. among psychiatric
disorders (rg ~ 0.6) or between lipids and CAD (rg ~ 0.25)22, they
nevertheless indicate potential shared genetic etiologies, especially
at certain chromosomes or regions, and are therefore worthy of
additional investigation into potential mechanisms using cross-
trait analysis and expression-trait analysis.
Cross-trait meta-analysis of migraine with BP measurements.
We conducted cross-trait meta-analysis to identify individual
SNPs that may share association with BP and migraine using the
Cross Phenotype Association (CPASSOC) package. Thirty-three
independent loci reached genome-wide significance for combined
statistics (PCPASSOC ≤ 5 × 10−08) and suggestive trait-specific
significance (PGWAS ≤ 1 × 10−05) for migraine and at least one BP
measurement (Supplementary Tables 3–5), 19 of which were
previously reported migraine loci, including PHACTR1, LRP1,
FHL5, C7orf10, MPPED2, CFDP1, and SLC24A3. Nine of the
remaining 14 shared loci (Table 2) were replicated at nominal
significance level in the independent migraine association study
using UK Biobank data, and 10 of them were also related with
broadly-defined headache (P < 0.05, Supplementary Table 6).
Among the candidate migraine loci, lead SNP rs62155750 was
most significant (chr2q11.1, PCPASSOC= 5.42 × 10−34 for DBP
based on SHet statistic). Rs62155750 was a significant expression
quantitative trait locus (eQTL) for its nearby gene ADRA2B
(Supplementary Table 7), encoding the subtype B of the α2-
adrenergic receptor that regulates neurotransmitter release from
sympathetic nerves and adrenergic neurons in the central nervous
system23. Interestingly, this locus was related to migraine (P=
0.02 based on SHet statistic) but not broadly defined headache
(P= 0.55 based on SHet statistic) in the replication dataset
(Supplementary Table 6). The second strongest signal overall was
lead SNP rs1048483 (at chr17p13.3) that was associated with both
SBP (PCPASSOC= 9.29 × 10−27 based on SHet statistic) and PP
(PCPASSOC= 5.13 × 10−28 based on SHet statistic. Rs1048483
mapped to SMG6 that encodes a nonsense-mediated mRNA
decay factor, and is a significant eQTL for the nearby gene SSR
(Serine Racemase, Supplementary Table 8), which is responsible
for transforming L‐serine to D‐serine, a key co-agonist with
glutamate at N‐methyl‐D‐aspartate (NMDA) receptors24. Lead
SNP rs6438857 (at chr3q21.2, PCPASSOC= 2.64 × 10−22, 1.77 ×
10−23, 2.55 × 10−14 for DBP, SBP, and PP, respectively based
on SHet statistic) implicating ITGB5 was the only locus that was
shared between migraine and all the three BP measurements.
ITGB5 encodes a beta subunit of integrin (integrin alpha-V/beta-
5), which is a member of integrin family of heterodimeric
transmembrane cell surface receptors and has a role in vascular
permeability induced by vascular endothelial growth factor
(VEGF) in the systemic circulation25. COL4A1 at chr13q34 was
shared between migraine and DBP (lead SNP rs13260, PCPASSOC
= 8.69 × 10−15 based on SHet statistic) as well as PP (lead SNP
rs12875271, PCPASSOC= 6.29 × 10−12 based on SHet statistic).
COL4A1 encodes a type IV collagen alpha protein, and COL4A1






























































































































































































































































































































































































































































































































































































































Fig. 1 Local genetic correlation between migraine and BP traits at reported migraine loci using ρ-HESS and GWAS-PW. Colors represent the
significance level of local genetic correlation between migraine and blood pressure (BP) traits (DBP, SBP, and PP) using ρ-HESS (Pρ-HESS based on Wald
test), red for positive genetic correlation and blue for negative genetic correlation at the corresponding locus. Dots represent the estimated posterior
probability (PPA_3) that genetic associations with migraine and BP traits (DBP, SBP, and PP) co-localize at the corresponding locus, larger size indicate
larger posterior probability. Significant local genetic correlation between BP traits and migraine was observed at three regions: harboring gene FHL5,
C7orf10, and PLCE1, after controlling for multiple testing (Pρ-HESS < 0.05/1703, see details in Supplementary Table 1) and with high estimated posterior
probability (PPA_3 > 0.9, see details in Supplementary Table 2).
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of which also have migraine as a clinical feature26,27. TGFB1 at
chr19q13.2 (lead SNP rs1800470, PCPASSOC= 1.49 × 10−17 based
on SHet statistic) was shared between migraine and PP alone and
encodes a transforming growth factor-beta 1 protein (TGF-β1)
family member.
Cross-trait meta-analysis between migraine subtypes (MA and
MO) and BP showed that previous reported migraine loci,
including PHACTR1, LRP1, and FHL5, were shared between both
migraine subtypes and BP while locus rs4141663 implicating
ITGB5 was genome-wide significant in cross-trait meta-analysis
between MO and BP measurements, but not MA (Supplementary
Tables 9–14).
Transcriptome-wide association studies. We performed TWAS
to identify gene-level genetic overlap between BP and migraine.
There were 76 TWAS genes that were transcriptome-wide sig-
nificant for both migraine and at least one BP trait, most of which
were identified from gene expression in tissues of cardiovascular
and nervous system (Fig. 2). Restricting this list to shared genes
with independent signals (see Methods), we identified 23 genes that
were TWAS significant for both migraine and at least one of the BP
traits from tissues including artery, nerve, skin, esophagus mucosa,
and whole blood (Supplementary Tables 15–17), among which 12
were migraine candidate genes. Five of these 12 genes were also
identified by the cross-trait meta-analysis (ITGB5, SMG6, ADRA2B,
ANKDD1B, and KIAA0040). ITGB5, SMG6, and ADRA2B are
described above. Data on ANKDD1B and KIAA0040 were limited,
but ANKDD1B was previously suggested to have a shared role
between migraine and major depressive disorder (MDD)28. Other
gene-level genetic overlap between migraine and BP included genes
(CISD2, DMPK, and C12orf5) that were related to regulation of
calcium homeostasis and reactive oxygen species (ROS)29,30. TWAS
genes with independent effects shared by subtypes of migraine and
BP were consistent with findings for overall migraine at ITGB5,
while identifying additional associations at HMOX2 for MA and
BP, and HVCN1 and MANBA for MO and BP (Supplementary
Figs. 22–27, Supplementary Tables 18–23).
Instrumental variable analysis. Finally, we used bi-directional MR
instrumental analysis to develop evidence for causality in the rela-
tionship between BP and migraine. Genetically instrumented ele-
vated DBP and SBP, and decreased PP were associated with
increased risk of having migraine with odds ratios (OR) of 1.20 (95%
confidence interval [CI]= 1.15–1.25; Wald test P= 5.01 × 10−24)
and 1.05 (95% CI= 1.03–1.07; Wald test P= 2.34 × 10−06) per 10
mmHg increment of DBP and SBP, and 1.09 (95% CI=
1.05–1.14; Wald test P= 3.29 × 10−06) per 10 mmHg decrement
of PP (Table 3). There were also significant instrumental variable
estimates from migraine to BP. Reverse MR showed significant
negative instrumental effects per doubling odds of migraine on
SBP (estimate= 0.67 mmHg decrement, Wald test P= 1.01 × 10
−10) and PP (estimate= 0.55 mmHg decrement, Wald test P=
3.21 × 10−15), but not DBP (estimate= 0.08 mmHg decrement,
Wald test P= 0.45). All heterogeneity P-values were non-
significant (PHEIDI > 0.01) indicating at worst only subtle het-
erogeneity among retained instruments. In conditional analysis to
distinguish effects mediated by DBP from those mediated by SBP,
there was an increase in the instrumental association of high DBP
on migraine with conditioning on SBP (OR [95% CI]= 1.38
[1.30–1.46], Wald test P= 4.16 × 10−37), while an opposite effect
of high SBP on migraine with conditioning on DBP (OR [95%
CI]= 0.86 [0.83–0.90], Wald test P= 2.08 × 10−22). The diver-
ging instrumental effects of DBP and SBP on migraine were also
supported by restricting analysis to SNP instruments that were
non-significant (P > 0.05) for one measure but highly significant
(P < 1 × 10−5) for the other (Supplementary Fig. 28). For sig-
nificance thresholds of P < 5 × 10−8 or smaller, the instrumental
effects of DBP and SBP for migraine were associated respectively
with increased and decreased migraine susceptibility. The
instrumental variable analysis revealed consistent associations of
DBP SBP
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Fig. 2 Number of shared TWAS significant genes between migraine and BP traits across 48 GTEx tissues (version 7). The X axis shows the count of
genes from tissues in the GTEx database meeting significance thresholds for multiple testing for migraine and for each of the BP measures as indicated. The
Y axis lists GTEx tissues. Colors represent different tissue categories. The null hypothesis of TWAS is no expression-trait association (or genetic correlation
between expression and a trait) conditional on the observed GWAS statistics at the corresponding locus. The total number of TWAS gene-tissue pairs
being tested is 206,397 across 48 GTEx tissues. TWAS transcriptome-wide association studies, BP blood pressure, DBP diastolic blood pressure, SBP
systolic blood pressure, PP pulse pressure, No. number.
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elevated DBP and decreased PP with MO (OR [95% CI]= 1.34
[1.21–1.47], Wald test P= 1.24 × 10−09, OR [95% CI]= 1.16
[1.05, 1.28], Wald test P= 5.80 × 10−03, respectively), whereas no
significant association was observed for MA after controlling for
multiple testing (Table 3). Sensitivity analysis for the main MR
analysis using inverse-variance weighted (IVW), weighted med-
ian, simple median, and MR-Egger procedures suggested there
was no systematic bias due to pleiotropy (Supplementary
Table 24), and MR-Steiger results showed that all the causal
estimates were oriented in the intended direction (all PMR-Steiger <
0.05). Taken together, the instrumental analyses suggest a
potential causal role of elevated DBP on migraine susceptibility,
whereas conditional on DBP, SBP may be causally protective.
These relationships are also reflected in a potential inverse causal
relationship between PP and migraine.
We also applied MR to explore the potential role of causality in
anti-hypertensives for migraine prophylaxis effect by only
examining lead variants in targets of BP-lowering medications
(i.e. beta blocker: ADRB1, ACE inhibitor: ACE, calcium channel
blockers: CACNB2, CACNA1D, and CACNA1C)31. Instrumental
associations at these SNPs were directionally consistent with the
preceding findings but none was significant alone or in
combination (all P > 0.05), nor was any SNP strongly associated
with migraine alone (all P > 0.01) (Supplementary Table 25).
When applied to two cardiovascular comorbidities of migraine,
stroke and CAD, the instrumental methods suggested a prominent
role for SBP rather than DBP (Table 4). Although both SBP and
DBP were strongly associated with all stroke subtypes in the
primary analysis, conditioning by SPB attenuated the DBP effect for
all stroke subtypes except for large artery stroke (LAS), for which
there was a significant inverse DBP association. After conditioning
on DBP, SBP remained significantly associated with any stroke,
ischemic stroke, large artery stroke, and small vessel stroke.
Similarly, after conditioning on DBP, SBP was positively associated
with CAD, but DBP conditioned on SBP had an inverse association.
In sensitivity analysis restricted to SNP instruments that were
significant (P < 1 × 10−5) for one BP trait but non-significant for
the other (P > 0.05), SBP was inferred to have stronger effects than
DBP on CAD and LAS, for which the effect of DBP was protective
as observed in the conditional analysis (Supplementary Fig. 29). For
the other stroke outcomes, effects of SBP were stronger than or
comparable to effects of DBP, especially when using stronger SNP
instruments.
Discussion
The conclusions from our genetic analyses were highly consistent
and generally support observational associations of positive cor-
relation between BP and migraine32 but also qualify these asso-
ciations in important ways. We find the strongest association
between elevated DBP and increased migraine susceptibility.
Weaker genetic relationships of elevated SBP with migraine were
largely explained by effects on DBP, and conditional on DBP,
genetically determined SBP was inversely related to migraine
susceptibility. The latter relationship was supported by SNP
instruments exclusively associated with SBP and the reverse
direction instrumental variable analysis. Consistent with distinct
effects of SBP and DBP, greater genetically determined PP was
strongly associated with less susceptibility to migraine in the
instrumental variable analysis. Because we leveraged germline
genetic variation as instrumental variables from large indepen-
dent studies, our causal estimates will be less affected by reverse
causation and possibly also selection bias than inference about
Table 3 Bi-directional instrumental estimates between migraine and blood pressure using GSMR.
Exposure Outcome Covariates Direction Instrumental estimatesa se P-Bonferroni
DBP Any migraine — Forward 0.18 0.02 5.01 × 10−24
Reverse −0.11 0.07 0.45
MA — Forward 0.12 0.05 0.18
Reverseb
MO — Forward 0.29 0.05 1.24 × 10−09
Reverseb
SBP Any migraine — Forward 0.05 0.01 2.34 × 10−06
Reverse −0.97 0.15 1.01 × 10
−10
MA — Forward 0.04 0.03 1.00
Reverseb
MO — Forward 0.06 0.03 0.36
Reverseb
PP Any migraine — Forward −0.09 0.02 3.29 × 10−06
Reverse −0.79 0.10 3.21 × 10
−15
MA — Forward −0.06 0.05 1.00
Reverseb





DBP Any migraine SBP Forward 0.32 0.03 4.16 × 10−37
SBP Any migraine DBP Forward −0.15 0.02 2.08 × 10−22
GSMR Generalized summary-data-based Mendelian randomization, se standard error, DBP diastolic blood pressure, SBP systolic blood pressure, PP pulse pressure, MA migraine with aura, MO migraine
without aura.
P-values are based on two-sided Wald test and used Bonferroni correction.
aThe instrumental estimate is corresponding to 10 mmHg increment of blood pressure for the forward direction.
bToo few instruments to conduct reverse GSMR for migraine with aura and without aura (number of genome-wide significant index SNPs <10).
cConditional GSMR was performed by conditioning the exposure on the corresponding covariates (using mtCOJO, https://cnsgenomics.com/software/gcta/#mtCOJO and then using the conditioned
summary statistics to infer the instrumental estimates from the exposure to the outcome.
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relationships between BP and migraine from observational
epidemiology33,34. In fact, the findings from genetics are con-
cordant with at least one of the prior observational studies8.
Meanwhile, 9 replicating SNPs from cross-trait association
analysis as well as 12 genes from TWAS of both migraine and BP
suggested potential functions relevant to migraine. The five loci
identified in both SNP and TWAS analysis revealed potential
shared biological mechanisms in migraine and BP regulation
involving vascular development and endothelial function, neu-
rogenic inflammation, calcium homeostasis through proteins
encoded by ITGB5, SMG6, ADRA2B, ANKDD1B, and KIAA0040
and, in particular, functions of the α2-adrenergic receptor type B
encoded by ADRA2B. Neurotransmitters, such as glutamate,
serotonin (5-HT), dopamine (DA), noradrenalin (NE), substance
P, and calcitonin gene-related peptide (CGRP), have all been
identified as contributing causally to migraine35, as well as
potential therapeutic targets36,37, and all are related with the α2-
adrenergic receptor regulation38. Therefore, our results support
the role of α2-adrenergic receptor in migraine mechanisms.
In contrast to the results for the genetic effects of DBP and PP
on migraine, the genetic association between BP and cardiovas-
cular events was driven by SBP, consistent with the results from
observational studies39. This suggests that different mechanisms
may underlie BP associations with migraine compared to CVD.
Thus, observational associations of migraine with cardiovascular
events likely do not involve BP-based etiology in a trivial way, a
conclusion further supported by the larger MR effects of BP on
cardiovascular events compared to the MR effects of BP on
migraine. However, it is also possible that potential genetic het-
erogeneity in migraine or misclassification due to changes in
migraine presentation over time may have attenuated the MR
association between BP and migraine3.
This study comprehensively investigates the genetic-based
association between migraine and BP. The main strengths of our
study include large-scale genetic data (sample size up to 757,601),
independent replication of migraine candidate loci from cross-
trait meta-analysis, the use of multiple MR sensitivity analysis for
outliers, horizontal pleiotropy, and reverse causation, and the use
of exclusive SNP instruments for DBP or SBP that were sig-
nificant for one trait (P < 1.00 × 10−5) but non-significant (P >
0.05) for the other. However, we acknowledge limitations. First,
our conclusions are limited to a general susceptibility of migraine
and its major subtypes MA and MO but may not extend to
different migraine traits over time or forms of migraine that may
not arise from the common, population-based genetic suscept-
ibilities implicit in our datasets, e.g. familial forms of migraine.
Second, although the instrumental analysis focused on genetic
variation in targets of BP-lowering medications (beta blocker,
ACE inhibitor, and calcium channel blocker) was not significant,
it may also have been underpowered. Based on the combined
effects of SNPs in these genes on BP, we estimated there was only
<50% power at nominal significance to detect such instrumental
effects on migraine in our datasets40. Third, although our analysis
points to tissues and genes relevant to migraine susceptibility and
BP, more work is needed to identify individual cell types and
more detailed molecular mechanisms with the goal of developing
potential therapeutic strategies.
Nevertheless, the findings further our understanding of the long-
standing debate about the role of BP in migraine susceptibility, reveal
the prominent genetic-based role of DBP in migraine susceptibility,
and identify shared genetic components including ADRA2B, all of
which may provide insight into future migraine therapies.
Methods
Summary statistics from GWAS for migraine and blood pressure. We used the
most recent GWAS summary-level data from International Headache Genetics
Consortium (IHGC) for migraine (any migraine and two subtypes of migraine:
migraine with aura [MA] and migraine without aura [MO]) and from the Inter-
national Consortium of Blood Pressure-Genome Wide Association Studies (ICBP)
and UK Biobank (UKB) for three BP traits (SBP, DBP, and PP)3,41. The migraine
meta-analysis summary statistics combined 59,674 cases and 316,078 controls from
22 cohort level GWASs3, whereas the BP meta-analysis summary statistics com-
bined 757,601 participants from the UKB (N= 458,577) and ICBP (N= 299,024
across 77 cohorts)41. In the original GWASs, migraine and its two sub-forms (MA
and MO) were defined by diagnostic criteria from the International Headache
Society and the summary statistics were adjusted for age, sex, and principle
components where applicable in each sub-cohort3, whereas BP summary statistics
(including three traits: SBP, DBP, and PP) were adjusted for age, age2, sex, and
body mass index (BMI) in the parent study, and all sub-cohorts corrected for
hypertension treatment (+15/10 mmHg in the presence of any hypertensive
medication)41. All of the participants were of European descent with only a small
fraction of overlapping samples (N= 39,199, proportion of overlapping samples is
~10% for migraine summary statistics, and ~5% for BP summary statistics)
between migraine and BP traits. Analysis in the current study was restricted to
SNPs, at most ~7 million, which were common to GWASs for migraine and the BP
traits. To compare the instrumental effects of BP traits on migraine and two
migraine cardiovascular comorbidities, coronary artery disease (CAD) and stroke,
we used publicly available GWAS summary statistics from European descent
individuals for CAD and stroke from CARDIoGRAM and MEGASTROKE,
respectively42,43. To minimize the bias from overlapping samples when conducting
the instrumental analyses of BP with CAD and stroke, we used BP GWAS
Table 4 Instrumental estimates between blood pressure and cardiovascular diseases (stroke and CAD) using GSMR.
Exposure Outcome Direction GSMRa Conditional GSMRb
Instrumental estimates se P Covariates Instrumental estimates se P
DBP AS Forward 0.50 0.03 1.82E-47 SBP −0.04 0.03 0.24
SBP Forward 0.31 0.02 9.49E-61 DBP 0.13 0.02 1.04E-12
DBP IS Forward 0.49 0.04 1.36E-38 SBP −0.1 0.03 3.05E-03
SBP Forward 0.30 0.02 2.36E-51 DBP 0.19 0.02 4.10E-22
DBP LAS Forward 0.59 0.09 9.90E-11 SBP −0.67 0.08 1.10E-15
SBP Forward 0.56 0.05 6.28E-30 DBP 0.49 0.05 2.70E-25
DBP CES Forward 0.27 0.07 9.67E-05 SBP 0.01 0.06 0.84
SBP Forward 0.17 0.04 4.36E-06 DBP 0.06 0.04 0.10
DBP SVS Forward 0.75 0.09 2.11E-18 SBP 0.12 0.08 0.12
SBP Forward 0.39 0.05 2.62E-17 DBP 0.17 0.04 6.65E-05
DBP CAD Forward 0.59 0.04 3.69E-58 SBP −0.19 0.03 2.83E-08
SBP Forward 0.34 0.02 3.87E-71 DBP 0.2 0.02 6.56E-26
GSMR Generalized summary-data-based Mendelian randomization, se standard error, DBP diastolic blood pressure, SBP systolic blood pressure, AS any stroke, IS ischemic stroke, LAS large artery stroke,
CES cardioembolic stroke, SVD small vessel stroke, CAD coronary artery disease.
P-values are based on two-sided Wald test.
aThe instrumental estimate is corresponding to 10 mmHg increment of blood pressure on the corresponding outcome.
bConditional GSMR was performed by conditioning the exposure on the corresponding covariates (using mtCOJO, https://cnsgenomics.com/software/gcta/#mtCOJO) and then use the conditioned
summary statistics to infer the instrumental estimates from the exposure to the outcome.
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summary statistics (N= 361,194) from the UK Biobank, which is publicly available
at http://www.nealelab.is/uk-biobank/44. All participants provided written
informed consent to each of the sub-cohort of the consortium.
Genetic correlation analysis. To evaluate genetic correlation between migraine and
BP, we used conventional cross-trait linkage disequilibrium (LD) score regression
(LDSC)17 and the more recent genetic covariance analyzer (GNOVA)45. For LDSC,
we used precomputed LD-scores derived from ~1.2 million common- and well-
imputed SNPs in European populations as represented in the Hapmap3 reference
panel excluding the HLA region17. With GNOVA, which is potentially more powerful
than LDSC45, we estimated the genetic correlation across ~5 million well-imputed
SNPs in the 1000 Genomes Project and partitioned the estimates among categories of
SNPs defined by 11 functional categories46, quartiles of MAF, and regions implicated
in transcription for seven broadly-defined tissue types45. Both LDSC and GNOVA
controlled for potential overlapping samples between each pair of traits17,45.
Local genetic correlation. We estimated local genetic correlations between
migraine and BP traits in 1703 pre-specified LD-independent segments with both
ρ-HESS18 and GWAS-PW47. Both methods are designed to identify small con-
tiguous regions of the genome in which the genetic associations with two traits are
locally concordant. However, they use different approaches. ρ-HESS quantifies the
local genetic covariance (and correlation) and P-values (Pρ-HESS) between pairs of
traits at local regions18, whereas GWAS-PW uses a Bayesian framework to estimate
the posterior probability (PPA_3) that genetic associations with the two traits co-
localize using priors that are learned from the data47. BP and migraine were
considered to have genetic correlation at local region if Pρ-HESS was significant after
correcting for multiple testing (Pρ-HESS < 0.05/1703) and PPA_3 from GWAS-PW
was larger than 0.9.
Cross-trait meta-analysis between migraine and BP traits. We conducted
pairwise cross-trait meta-analysis using Cross Phenotype Association (CPASSOC)19
through the statistic SHet that implements a sample size-weighted, fixed effect meta-
analysis of the association statistics from the individual traits while modeling genetic
covariance from all sources. In these analyses, we used total sample size values directly
from the summary statistics file for BP and an average effective sample size for
migraine48. The cross-trait meta-analysis was not inflated by observing a mean ratio
of (LDSC intercept-1)/(mean(χ2)− 1) at 0.05 (Supplementary Figs. 1–9). Replication
of migraine candidate associations from CPASSOC was performed using an inde-
pendent dataset from UK Biobank (using data from data field 20002 and 6159 for
migraine and recent headache, respectively, see details in Supplementary Note 1).
Transcriptome-wide association studies. To identify genes whose expression
pattern across tissues implicates etiology or biological mechanisms shared by
migraine and the BP measures, we performed TWAS49. With TWAS, we compared
gene-based models of genetic effects on tissue-specific gene expression from GTEx
v.7 for migraine and the BP measures from the GWAS summary statistics to
estimate strength of association between concordant gene-based genetic influences
on gene expression on migraine or BP. In total, we performed 48 TWASs for each
trait, one tissue–trait pair at a time. The null hypothesis of TWAS is no
expression–trait association (or genetic correlation between expression and a trait)
conditional on the observed GWAS statistics at the locus. In practice, a permu-
tation test based on 1000 resampling iterations was run for each TWAS gene to
ensure that the TWAS false positive rate was well controlled49. We applied Bon-
ferroni correction to identify significant expression-trait associations adjusted for
multiple comparisons for all gene–tissue pairs tested for each trait (~200,000 gene-
tissue pairs in total, significant expression–trait associations were defined as
PBonferroni < 0.05), and then identified genes that had Bonferroni significant asso-
ciations for both migraine and BP. We further tested for conditional relationships
among the shared genes to identify an independent set of gene-based genetic
models using an extension of TWAS that leverages previous methods for joint/
conditional tests of SNPs using summary statistics20 (Supplementary Note 2).
Generalized summary-data-based Mendelian randomization. To examine evi-
dence for potential causal relationships between migraine and BP, we conducted
instrumental variable analysis using bi-directional MR implemented in generalized
summary-data-based Mendelian randomization (GSMR)21. GSMR applies strict cri-
teria to select independent SNP instruments and extends conventional MR by
accounting for the sampling variance in the genetic effects on both exposure (bzx) and
outcome (bzy) in estimating the instrumental effect. Further, as pleiotropy is an
important potential confounder that could bias the estimates and possibly result in an
inflated test-statistic in MR, we used heterogeneity criteria in HEIDI (heterogeneity in
dependent instruments, PHEIDI < 0.01) in the GSMR package to exclude likely pleio-
tropic SNPs from the analysis. To evaluate separate effects of SBP and DBP on
migraine, we performed conditional instrumental analysis using mtCOJO (multi-
trait-based conditional and joint analysis), also within GSMR, with a two-step pro-
cedure requiring only the GWAS summary statistics21. SNP effects on SBP (y) were
adjusted for effects on DBP (x) (or vice-versa) (i.e. bxy obtained from GSMR) in step
1, and then the adjusted instruments were used to derive the conditional instrumental
estimate in step 2. P-values were corrected for multiple testing using Bonferroni
criteria. We conducted sensitivity analyses using conventional inverse-variance
weighted (IVW) MR, weighted median, simple median, MR-egger (Egger regression),
and MR-Steiger (Supplementary Note 3). As migraine is a binary variable, we
interpreted the reverse causal estimates as the average change in BP per doubling
(twofold increase) in the odds of migraine, which could be obtained by multiplying
the reverse causal estimate by 0.693 (loge2)50.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Summary-level data for CAD (CARDIoGRAM), Stroke (MEGASTROKE), and BP
(International Consortium of Blood Pressure genetics [ICBP] and the UK Biobank
[UKB]) are publicly available at: http://www.cardiogramplusc4d.org/data-downloads/
and http://www.megastroke.org/download.html; and http://www.nealelab.is/uk-biobank/.
Summary-level data (P < 1 × 10−5) from International Headache Genetics Consortium
(IHGC) for migraine are available here: http://www.headachegenetics.org/content/
datasets-and-cohorts. Individual level data from the UK Biobank (UKB) are available
upon application: https://www.ukbiobank.ac.uk/.
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